Fasting

Enzymedica Unveils Fasting Today: First-of-Its-Kind Product Revolutionizes Intermittent Fasting with Innovative Formula

Retrieved on: 
Thursday, May 2, 2024
Nutrient, Eating, Marketing, Fasting, Dicarboxylic acid, Ageing, Hunger, Body composition, Electrolyte, Water, Facial muscles, Dietary supplement

Intermittent fasting has become an increasingly popular health practice with growing consumer interest in recent years.

Key Points: 
  • Intermittent fasting has become an increasingly popular health practice with growing consumer interest in recent years.
  • Scientific research concludes that intermittent fasting supports weight management, increased energy levels, brain health and healthy aging.
  • Enzymedica formulated Fasting Today to support those embracing the practice of time-restricted dieting with added nutrients essential during fasting periods.
  • "We understand the growing interest in intermittent fasting and the importance of feeling your best during fasting periods.

Scotiabank supports the Moose Hide Campaign in its efforts to eliminate gender-based violence

Retrieved on: 
Tuesday, April 30, 2024
Knowledge, Woman, Violence, Partnership, Life, Fasting, Campaign, Bank, Scotiabank, Elder, Nursing

The Moose Hide Campaign marks an annual day of ceremony to take a stand against violence, including events and marches with fasting and teachings shared by Elders and Knowledge Keepers.

Key Points: 
  • The Moose Hide Campaign marks an annual day of ceremony to take a stand against violence, including events and marches with fasting and teachings shared by Elders and Knowledge Keepers.
  • "Through this partnership with the Moose Hide Campaign, Scotiabank is honoured to play a role in raising awareness about the importance of ending gender-based and domestic violence."
  • Scotiabank is distributing over 20,000 moose hide pins across Canadian branches for its employees to wear and share.
  • "Wearing the moose hide pin signifies your commitment to honour, respect and protect the women and children in your life and speak out against gender-based and domestic violence," said Raven Lacerte, Co-Founder of the Moose Hide Campaign.

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Retrieved on: 
Tuesday, April 23, 2024
Congenital hyperinsulinism, Birth defect, PES, Poster, CGM, Fasting, Hypoglycemia, Pharmaceutical industry

REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.

Key Points: 
  • REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.
  • Paul Thorton, M.D., of Cook Children’s Medical Center in Fort Worth, Texas, will present the poster, which details findings from the Company’s Phase 2 RIZE study evaluating the treatment of congenital hyperinsulinism (HI) with RZ358 in pediatric patients.
  • A Phase 3 study is currently underway.
  • For more information on the conference presentation schedule and to view the poster abstract, please visit the PES Annual Meeting website .

Equinox Hotels Revolutionizes Sleep Tourism with Inaugural Global Sleep Symposium

Retrieved on: 
Wednesday, April 24, 2024
Other Health, Other Travel, Other Consumer, Lodging, Destinations, General Health, Travel, Women, Men, Science, Vacation, Consumer, Other Science, Health, Research, Relaxation, Foodservice, Lead, Brain, University, Psychology, TED (conference), Yoga, Sleep, Hotel, Fasting, Movement, University of California, Berkeley, Melksham, Multimedia, Central nervous system, Equinox, Regeneration, Electronic, Longevity, Sound, UC

Equinox Hotels, renowned for its pioneering approach to high-performance luxury hospitality and sleep-focused innovation, announces the launch of its inaugural Global Sleep Symposium at Equinox Hotel New York on June 19th and 20th.

Key Points: 
  • Equinox Hotels, renowned for its pioneering approach to high-performance luxury hospitality and sleep-focused innovation, announces the launch of its inaugural Global Sleep Symposium at Equinox Hotel New York on June 19th and 20th.
  • This visionary two-day overnight event is set to redefine the landscape of sleep tourism by uniting global experts in sleep health and performance with Equinox Hotel's dynamic programming centered on movement, nutrition, regeneration, and community.
  • The two-day symposium signifies the culmination of years of boundary-pushing sleep innovation, positioning Equinox Hotels as the preeminent nexus for leaders in the sleep industry and enthusiasts alike, to converge, collaborate, and propel the discourse on sleep science and sleep tourism to new heights.
  • The Equinox Hotels Global Sleep Symposium transcends mere discussion; it offers an immersive experience aimed at enhancing every aspect of sleep quality, providing attendees with firsthand interactions to elevate their sleep understanding and practice.

Dr. Berg, ("The Knowledge Doc") Renowned Health Expert, Surpasses 11.5 Million YouTube Subscribers Amidst Soaring Website Traffic!

Retrieved on: 
Monday, April 15, 2024
Knowledge, Health, Fasting, Science, Movement, Mobile phone

ALEXANDRIA, Va., April 15, 2024 /PRNewswire-PRWeb/ -- In a groundbreaking industry development, Dr. Eric Berg, affectionately known as "The Knowledge Doc™," has reached a monumental milestone, surpassing 11.5 million subscribers on his YouTube channel. Alongside this, his website - https://www.drberg.com/ has seen an impressive influx of over one million unique monthly visitors. These achievements highlight a burgeoning shift towards healthy living, underpinned by Dr. Berg's expert guidance on Healthy Keto® and intermittent fasting.

Key Points: 
  • ALEXANDRIA, Va., April 15, 2024 /PRNewswire-PRWeb/ -- In a groundbreaking industry development, Dr. Eric Berg, affectionately known as "The Knowledge Doc™," has reached a monumental milestone, surpassing 11.5 million subscribers on his YouTube channel.
  • Alongside this, his website - https://www.drberg.com/ has seen an impressive influx of over one million unique monthly visitors.
  • Surpassing 11.5 million subscribers reflects a widespread eagerness to embrace health knowledge that's scientifically sound yet easily understood.
  • His commitment to empowering individuals with the knowledge to make informed health decisions continues to propel the channel's growth, cementing his role as a pivotal figure in online health education.

Virtue Recovery Offers Holistic Therapy Options for Enhanced Rehabilitation

Retrieved on: 
Wednesday, April 10, 2024
Patient, CDO, Ice, Hope, Holism, Blood pressure, MAT, Health, Steam, Research, Water, Hydrotherapy, Skin temperature, Heart rate, Psychotherapy, Yoga, Disease, Fasting, Mental health, Addiction, Mindfulness, Breathing, Cognitive behavioral therapy, Music, Meditation, Music therapy, Rehabilitation, CBT, Walking, Virtue, Swimming, Nursing

LAS VEGAS, April 10, 2024 /PRNewswire-PRWeb/ --

Key Points: 
  • Virtue Recovery Center is proud to announce an expanded suite of holistic therapy options designed to complement its evidence-based rehabilitation programs.
  • Embracing a comprehensive path to recovery, Virtue Recovery Center integrates innovative, traditional, and additional therapies, including holistic approaches to nurture the mind, body, and spirit.
  • "Virtue Recovery Center embraces the addition of a holistic treatment approach because we understand that recovery transcends the physical aspect of addiction.
  • Virtue Recovery Center's methodology embraces the integration of traditional rehabilitation with holistic therapies, emphasizing a holistic and evidence-based care approach aimed at treating the full spectrum of addiction.

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Health, Regeneration, Learning, Glycated hemoglobin, Menin, C-peptide, Insulin, Diabetes, AUC, Patient, Fasting, MD, Metformin, Person, Cancer, Safety, A1C, DSM-IV codes, Pharmaceutical industry

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced initial response data from the first two type 1 diabetes patients treated with BMF-219 in the ongoing Phase II study (COVALENT-112).

Key Points: 
  • “We are very excited to announce the initial response data from the first two type 1 diabetes patients enrolled in the COVALENT-112 study.
  • Both patients showed improvement in measures of beta-cell function after only 4 weeks of dosing with BMF-219.
  • The trial includes an open label portion for adults with type 1 diabetes up to 15 years since diagnosis.
  • It has been exciting to participate in this study and explore this new pathway for the benefit of our patients.

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

Retrieved on: 
Sunday, April 7, 2024
TGS, AP, Ionis, Incidence, Abdominal pain, IONS, Webcast, Patient, NEJM, Fasting, American College, Ionis Pharmaceuticals, FCS, ACC, Triglyceride, Annual general meeting, Medicine, Pharmaceutical industry

CARLSBAD, Calif., April 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (FCS). The olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides (TGs) in patients with genetically validated FCS at six months. In addition, olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprotein C-III (apoC-III) levels. Importantly, olezarsen reduced the incidence of acute pancreatitis (AP) events over the 12-month treatment period compared to placebo. Olezarsen also demonstrated a favorable safety and tolerability profile. These results were presented in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia and published simultaneously in The New England Journal of Medicine (NEJM). Based on these data, Ionis is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.

Key Points: 
  • Based on these data, Ionis is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.
  • In the study, patients were treated with olezarsen 80 mg (n=22), 50 mg (n=21) or placebo (n=23) once every four weeks.
  • Serious AEs occurred in 14% of patients treated with olezarsen 80 mg, 19% treated with olezarsen 50 mg, and 39% treated with placebo.
  • Ionis will host a webcast to discuss the detailed results from the Balance study on Monday, April 8 at 10:00 am ET.

CopilotIQ Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024

Retrieved on: 
Tuesday, March 19, 2024
Cardiology, Software, General Health, Health, Diabetes, Artificial Intelligence, Health Technology, Technology, Blood pressure, Glucose, Editorial, Culture, Organization, Entrepreneurship, MIC, Physician, Biomarker, AI, Hope, Anomaly, Fasting, Hyperglycemia, ITunes, Most, Medicare, BMI, Nursing, Medicare Advantage, Hypertension, Human, Pharmaceutical industry

CopilotIQ , the company reshaping care for older Americans with diabetes and hypertension, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024.

Key Points: 
  • CopilotIQ , the company reshaping care for older Americans with diabetes and hypertension, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024.
  • Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.
  • The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year.
  • This event celebrates the Most Innovative Companies honorees and provides an inside look at cutting-edge business trends and what it takes to innovate in 2024.

United States Weight Loss Market Report 2024: Market Performance of 2023, Analysis of 2020-2023 & Forecasts to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
General Health, Pharmaceutical, Fitness & Nutrition, Health, Bankruptcy, Obesity, ALL, Weight loss, Nutrisystem, Fasting, News, Noom, WW, Diet, Pain, FDA, Boston, Physician, Advertising, Dietary supplement

Weight Loss Market: 2024 Status Report & Forecast" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Weight Loss Market: 2024 Status Report & Forecast" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering.
  • This report presents a wrap-up of 2023 performance for the U.S. weight loss market during the obesity drugs market explosion and a forecast for 2024.
  • Nearly all non-medical segments of the market have felt the pain of declining sales, and 26,500 weight loss coaches have lost their jobs.
  • However, more physicians are adding weight loss to their practices, bariatric surgeries are hitting new highs, and caseloads/revenues at medical weight loss franchises and at bariatricians are growing.